

DL-033198\_08

March 31, 1998

Meritus PLS, Inc.  
(formerly Meritus Health Systems, Inc.)  
ATTN: Mr. Joel Dobson  
Administrator  
233 Hershberger Road, Suite 200  
Roanoke, VA 24012

SUBJECT: TRANSMITTAL AND EXPLANATION OF AMENDMENT TO LICENSE NO. 45-25194-01 (REFERENCE CONTROL NO. 257810; DOCKET NO. 030-32701)

Dear Mr. Dobson:

Enclosed please find Amendment No. 10 to your NRC material license. Changes to the license are printed in **BOLD** typeface.

Please review the document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify this office (ATTN: Ms. Diane Heim at (404) 562-4723) so that we can provide appropriate corrections and answers.

Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR 19, "Notice, Instructions and Reports to Workers; Inspections and Investigations"; 10 CFR 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC, in writing, within 30 days:
  - a. when an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or
  - b. when the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).
3. In accordance with 10 CFR 30.36(d) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:
  - a. when you decide to terminate all activities involving materials authorized under the license; or
  - b. when you decide to terminate licensed activities in a separate building or outdoor area identified on your license.

4. Request and obtain a license amendment before you:
  - a. receive or use byproduct material for a clinical procedure permitted under 10 CFR 35 but not permitted by your license issued pursuant to this part.
  - b. permit anyone, not authorized under 10 CFR 35, Subpart J, to work as an authorized user under a license for medical use of byproduct material;
  - c. permit anyone, not authorized under 10 CFR 35, Subpart J, to work as a Radiation Safety Officer or Nuclear Pharmacist, under a license for medical use of byproduct material;
  - d. order byproduct material in excess of the amount, or a different radionuclide or form, other than authorized on the license;
  - e. add or change the areas of use or address (or addresses) of use identified in the license application or on the license; or
  - f. change ownership of your organization.
5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. Transfer of licensed materials must be consistent with 10 CFR 30.41, 40.51 or 70.42, as applicable. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signature on the application should be the licensee or a certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a Notice of Violation, or imposition of a Civil Penalty, or an order suspending, modifying or revoking your license as specified in the "General Statement of Policy and Procedures for NRC Enforcement Actions," NUREG-1600 (7/95). Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken against those who do not achieve the necessary attention to detail and standard of compliance expected of licensees.

Meritus PLS. Inc.

3

Thank you for your cooperation.

Sincerely,



Jay L. Henson, License Reviewer  
Division of Nuclear Materials Safety

- Enclosures: 1. Amendment No. 10  
License No. 45-25194-01  
2. NRC Form 313

OFFICE	RII:DNRS	RII:DNRS											
SIGNATURE													
NAME	J. Henson	C. Casey											
DATE	3/27/98	3/31/98	3/ /98	3/ /98	3/ /98	3/ /98	3/ /98	3/ /98	3/ /98	3/ /98	3/ /98	3/ /98	3/ /98
COPY?	YES NO	YES NO	YES NO	YES NO	YES NO	YES NO	YES NO	YES NO	YES NO	YES NO	YES NO	YES NO	YES NO

OFFICIAL RECORD COPY

DOCUMENT NAME: G:\MSS11\DNRS\COVLTR\257810.JLN

This is to acknowledge the receipt of your letter/application dated

11/16/96 and to inform you that the initial processing which includes an administrative review has been performed.

There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

---

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number \_\_\_\_\_  
When calling to inquire about this action, please refer to this control number.  
You may call me at 404-562-4723

Sincerely,

Licensing Assistant

*11/16/96*

LICENSE FEE TRANSMITTAL

A. REGION II

1. APPLICATION ATTACHED

Applicant/Licensee: MERITUS PLS. INC.  
Received Date: 980209  
Docket No: 3032701  
Control No.: 257810  
License No.: 45-25194-01  
Action Type: Amendment

2. FEE ATTACHED

Amount: 460.00  
Check No.: 6495

3. COMMENTS

Signed DIANE HEIM  
Date 2/10/98

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / )

1. Fee Category and Amount: 7C 2B 460

2. Correct Fee Paid, Application may be processed for:

Amendment   
Renewal \_\_\_\_\_  
License \_\_\_\_\_

3. OTHER \_\_\_\_\_

Signed Patricia Messier  
Date 2/17/98

Log	<u>Feb 4 II</u>
Remitter	
Check No.	<u>6495</u>
Amount	<u>460</u>
Fee Category	<u>7C 2B</u>
Type of Fee	<u>Amnd</u>
Date Check Rec'd.	
Date Completed	<u>2/17/98</u>
By	<u>[Signature]</u>

**OFFICIAL RECORD OF MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Meritus PLS, Inc. (formerly Meritus Health Systems, Inc.)</p> <p>2. 233 Hershberger Road, Suite 200  Roanoke, Virginia 24012</p>	<p>In accordance with letter dated February 4, 1998</p> <p>3. License number 45-25194-11 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date July 31, 2002</p> <hr/> <p>5. Docket No. 030-32701 Reference No.</p>
--	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material identified in 10 CFR 35.100</p> <p>B. Any byproduct material identified in 10 CFR 35.200</p> <p>C. Uranium depleted in uranium 235</p>	<p>7. Chemical and/or physical form</p> <p>A. Any radiopharmaceutical identified in 10 CFR 35.100</p> <p>B. Any radiopharmaceutical identified in 10 CFR 35.200, except xenon 133</p> <p>C. Metal</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed, except no single patient dose of I-125 or I-131 to exceed 1.11 megabecquerels (30 µCi)</p> <p>C. 999 kilograms</p>
--	---	---

9. Authorized Use:
- A. Medical use in uptake, dilution and excretion studies identified in 10 CFR 35.100
  - B. Medical use in imaging and localization studies identified in 10 CFR 35.200
  - C. Shielding for molybdenum-99/technetium-99m generators

CONDITIONS

10. A. Licensed material shall be used only at temporary job locations of the licensee in Virginia and West Virginia.
- B. Notwithstanding the requirement of 10 CFR 35.80(a), the licensee may transport molybdenum-99/technetium-99m generators to temporary job locations for use only within the mobile nuclear medicine facility.

9804160269 980331  
PDR ADOCK 03032701  
C PDR

ML 20

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

45-25194-01

Docket or Reference Number

030-32701

Amendment No. 10

10. C. Licensed materials may only be delivered to the licensee's mobile unit, the primary storage location, while at:
- (1) Page Memorial Hospital, 200 Memorial Drive, Luray, Virginia;
  - (2) Summersville Memorial Hospital, 400 Fairview Heights Road, Summersville, West Virginia; and
  - (3) Plateau Medical Center, 430 Main Street, Oak Hill, West Virginia.
  - (4) Williamson Memorial Hospital, 1950 Alderson Street, Williamson, West Virginia.
  - (5) Dickenson County Medical Center Hospital Drive, Clintwood, Virginia.
  - (6) Community Radiology of Virginia, Inc., 2000 Leatherwood Lane, Bluefield, Virginia and/or 2001 Leatherwood Lane, Bluefield, West Virginia.
  - (7) Welsh Emergency Hospital, 454 McDowell Street, Welsh, West Virginia.
  - (8) The Heart Institute of Southern West Virginia, 110 South Court Street, Lewisburg, West Virginia.
  - (9) Grant Memorial Hospital, Route 55 West, Petersburg, West Virginia.
  - (10) Weaver Medical Associates, P.C., 505 Leigh Street #102, Richmond, Virginia.
  - (11) Cardiac Care Associates, 8201 Greensboro Drive, Vienna, Virginia.
  - (12) Radiology Associates, PC, 13890 Braddock Road, Centreville, Virginia.
  - (13) Commonwealth Valley Imaging, 106 North Lee Street, #1, Luray, Virginia.
  - (14) Carilion Bedford Memorial Hospital, 1613 Oakwood Street, Bedford, Virginia.
  - (15) Montgomery General Hospital, 401 Sixth Street, Montgomery, West Virginia.
  - (16) Community Radiology of Virginia, 1000 Leatherwood Lane, Bluefield, West Virginia and/or 1616 W. Cumberland Road, Bluefield, West Virginia
11. Radiation Safety Officer: Francis H. George, M.D.
12. Authorized users Material and Use
- A. Francis H. George, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
  - B. Mohammad Ebrahim Dehgen, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
  - C. Walter W. Wolfe, M.D. Medical uses described in 10 CFR 35.100 and 35.200.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

45-25194-01

Docket or Reference Number

030-32701

Amendment No. 10

12. D. Ann Jackson Smith, M.D. Technetium 99m radiopharmaceuticals for cardiac imaging studies.
- E. Michael E. Shahan, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- F. Ezad N. Ahmad, M.D. Technetium 99m radiopharmaceuticals for cardiac imaging studies.
- G. M. R. Ramakrishnan, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- H. Je Hyun Kim, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- I. Steven A. Artz, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- J. Ali Goodarzi, M.D. Medical uses described in 10 CFR 35.100 and §35.200.
- K. Stephen P. Raskin, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- L. Emily Wang Lewis, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- M. F. Caryle Stebner, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- N. M. S. Kim, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- O. J. K. Kim, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- P. Yvonne J. Weaver, M.D. Technetium 99m radiopharmaceuticals for cardiac imaging.
- Q. Vincent J. Mascatello, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- R. Scot A. LeBolt, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- S. Dennis Joseph McCabe, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- T. Mark Cameron Lopiano, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- U. Herbert P. Rhodes, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
- V. Judith Perrotto, M.D. Medical uses described in 10 CFR 35.100 and 35.200.
13. Prior to vacating or releasing any field office or storage location authorized by this license, the licensee shall notify the Nuclear Regulatory Commission in accordance with the provisions of 10 CFR 30.36.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

45-25194-01

Docket or Reference Number

030-32701

Amendment No. 10

14. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum specified 10 CFR 30.35 for establishing decommissioning financial assurance.
16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated March 4, 1992
- B. Letters dated:
- (1) April 28, 1992
  - (2) May 20, 1992
  - (3) May 26, 1992
  - (4) July 23, 1992
  - (5) September 30, 1992

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

45-25194-01

Docket or Reference Number

030-32701

Amendment No. 10

16. B. (6) December 28, 1992  
 (7) March 15, 1994 [add place of use and delete alternate RSO]  
 (8) February 24, 1995 [add users, linearity kit, RSC structure, mobile sites]  
 (9) June 9, 1995 [added information for authorized user]  
 (10) November 22, 1995 [Add new users and new temporary jobsites]  
 (11) March 25, 1996 [Description of new mobile nuclear medicine unit]  
 (12) May 14, 1996 [Addition of two authorized users; and Addition of another hospital as a location of use]  
 (13) May 21, 1996 [Facsimile regarding deletion of an authorized user; and Extension of expiration date in accordance with 10 CFR 30.36]  
 (14) August 20, 1996 (Add users and places of use, change name)  
 (15) April 9, 1997 [add places of use and user]  
 (16) May 15, 1997 [add user]  
 (17) February 4, 1998 [add user and places of use]

C. Letter and attachments received April 19, 1993

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

JAY L. HENSON

DATE MAR 31 1998

BY

*Jay L. Henson*

Region II, Division of Nuclear Materials Safety  
 61 Forsyth Street, Suite 23T85  
 Atlanta, GA 30303